Exclusive Summary

• Promising First-in-Class 4-target (VEGF-A/C/D & Ang-2) fusion protein, effectively overcoming the compensatory resistance mechanisms triggered by current anti-VEGF therapies.
• Preclinical data demonstrates overwhelming potency advantages head-to-head against standard-of-care Vabysmo (~18x increase in VEGF-A inhibition and ~36x in Ang-2 inhibition).
• Presents revolutionary ultra-long-acting potential, aiming for a dosing interval of 4 months or longer (≥Q4M), significantly reducing the burden on patients and healthcare systems.
• Targets the multi-billion-dollar global markets for wAMD, DME, and RVO, making it an ideal license-out asset for international big pharma seeking next-generation ophthalmic pipelines.

Asset Materials

Contact Us for Full Materials